Lacosamide may improve cognition in patients with focal epilepsy

EpiTrack to compare cognitive side effects of lacosamide and carbamazepine

Claudio Liguori, Francesca Izzi, Natalia Manfredi, Nicola Biagio Mercuri, Fabio Placidi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Carbamazepine (CBZ) is a first generation anti-seizure drug, considered as first choice therapy in focal epilepsy but associated with cognitive side effects. Lacosamide (LCM) is a third-generation anti-seizure drug approved for treating focal epilepsy. This case series documented the comparable efficacy of LCM and CBZ as first add on treatments in patients affected by uncontrolled focal seizures. LCM showed an increase in EpiTrack scores, which measure cognitive abilities, at follow-up compared to CBZ. This preliminary data may represent the basis for future prospective studies aimed at comparing the long-term cognitive side effects of LCM and CBZ.

Original languageEnglish
Pages (from-to)35-37
Number of pages3
JournalEpilepsy and Behavior Case Reports
Volume10
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Partial Epilepsy
Carbamazepine
Cognition
Seizures
Aptitude
Pharmaceutical Preparations
Prospective Studies
lacosamide
Therapeutics

Keywords

  • Carbamazepine
  • Cognition
  • EpiTrack
  • Focal epilepsy
  • Lacosamide

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Behavioral Neuroscience

Cite this

Lacosamide may improve cognition in patients with focal epilepsy : EpiTrack to compare cognitive side effects of lacosamide and carbamazepine. / Liguori, Claudio; Izzi, Francesca; Manfredi, Natalia; Mercuri, Nicola Biagio; Placidi, Fabio.

In: Epilepsy and Behavior Case Reports, Vol. 10, 01.01.2018, p. 35-37.

Research output: Contribution to journalArticle

@article{4e63ab794b3848aa869c79ec9b36624e,
title = "Lacosamide may improve cognition in patients with focal epilepsy: EpiTrack to compare cognitive side effects of lacosamide and carbamazepine",
abstract = "Carbamazepine (CBZ) is a first generation anti-seizure drug, considered as first choice therapy in focal epilepsy but associated with cognitive side effects. Lacosamide (LCM) is a third-generation anti-seizure drug approved for treating focal epilepsy. This case series documented the comparable efficacy of LCM and CBZ as first add on treatments in patients affected by uncontrolled focal seizures. LCM showed an increase in EpiTrack scores, which measure cognitive abilities, at follow-up compared to CBZ. This preliminary data may represent the basis for future prospective studies aimed at comparing the long-term cognitive side effects of LCM and CBZ.",
keywords = "Carbamazepine, Cognition, EpiTrack, Focal epilepsy, Lacosamide",
author = "Claudio Liguori and Francesca Izzi and Natalia Manfredi and Mercuri, {Nicola Biagio} and Fabio Placidi",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.ebcr.2018.02.004",
language = "English",
volume = "10",
pages = "35--37",
journal = "Epilepsy and Behavior Case Reports",
issn = "2213-3232",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Lacosamide may improve cognition in patients with focal epilepsy

T2 - EpiTrack to compare cognitive side effects of lacosamide and carbamazepine

AU - Liguori, Claudio

AU - Izzi, Francesca

AU - Manfredi, Natalia

AU - Mercuri, Nicola Biagio

AU - Placidi, Fabio

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Carbamazepine (CBZ) is a first generation anti-seizure drug, considered as first choice therapy in focal epilepsy but associated with cognitive side effects. Lacosamide (LCM) is a third-generation anti-seizure drug approved for treating focal epilepsy. This case series documented the comparable efficacy of LCM and CBZ as first add on treatments in patients affected by uncontrolled focal seizures. LCM showed an increase in EpiTrack scores, which measure cognitive abilities, at follow-up compared to CBZ. This preliminary data may represent the basis for future prospective studies aimed at comparing the long-term cognitive side effects of LCM and CBZ.

AB - Carbamazepine (CBZ) is a first generation anti-seizure drug, considered as first choice therapy in focal epilepsy but associated with cognitive side effects. Lacosamide (LCM) is a third-generation anti-seizure drug approved for treating focal epilepsy. This case series documented the comparable efficacy of LCM and CBZ as first add on treatments in patients affected by uncontrolled focal seizures. LCM showed an increase in EpiTrack scores, which measure cognitive abilities, at follow-up compared to CBZ. This preliminary data may represent the basis for future prospective studies aimed at comparing the long-term cognitive side effects of LCM and CBZ.

KW - Carbamazepine

KW - Cognition

KW - EpiTrack

KW - Focal epilepsy

KW - Lacosamide

UR - http://www.scopus.com/inward/record.url?scp=85046157915&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046157915&partnerID=8YFLogxK

U2 - 10.1016/j.ebcr.2018.02.004

DO - 10.1016/j.ebcr.2018.02.004

M3 - Article

VL - 10

SP - 35

EP - 37

JO - Epilepsy and Behavior Case Reports

JF - Epilepsy and Behavior Case Reports

SN - 2213-3232

ER -